-
Immune-Checkpoint Inhibition in Cancer Prevention(Post)
Harnessing Immune-Checkpoint Inhibition for Cancer Prevention Immune-checkpoint inhibition (ICI) has emerged as a pivotal strategy in cancer therapy, particularly in the context of tu
Custom Protein(Page)Custom Protein & Peptide Service | Assay Genie
Custom Cell Lines(Page)Custom Protein & Peptide Service | Assay Genie
Zilovertamab: Unlocking the Potential of ROR1-Targeted Therapy(Post)Quick Facts About ZilovertamabWhat is Zilovertamab?Zilovertamab is a monoclonal antibody targeting ROR1, a receptor tyrosine kinase overexpressed in hematologic cancers and solid tumors.
PD-L1 in Cancer Immunotherapy: Key Insights(Post)PD-L1 in Cancer Immunotherapy: Insights from Recent ResearchRecent advancements in cancer immunotherapy have underscored the critical role of programmed death-ligand 1 (PD-L1) in mediating immune evas
LPS ELISA Troubleshooting: The Importance of Sample Nature(Post)Quick answer A researcher measuring circulating lipopolysaccharide (LPS) in human serum with our LPS ELISA saw almost no color, even after 30 minutes with substrate. Samples had been test
Validate Western Blot Antibodies: Datasheet Checks Labs Should Ask(Post)Validate Western Blot Antibodies: Datasheet Checks Labs Should Ask Reliable results come from antibodies validated specifically for denatured western blot conditions: recombinant monoclonals or well-
Vibostolimab: Mechanism, Clinical Applications, and Research Potential in Oncology(Post)Key Facts About VibostolimabWhat is Vibostolimab?Vibostolimab is an anti-TIGIT monoclonal antibody developed by Merck, targeting immune checkpoint pathways to enhance anti-tumor immunity
Enapotamab: Advancing Cancer Research with Innovative Therapeutics(Post)Quick Facts About EnapotamabWhat is Enapotamab?Enapotamab is an experimental antibody-drug conjugate (ADC) developed to target tumor cells selectively, offering new hope in cancer treatm
Ruplizumab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About RuplizumabWhat is Ruplizumab?Ruplizumab is an investigational monoclonal antibody designed to target CD47, a protein that helps cancer cells evade immune detection.What
Enfortumab Vedotin: Unveiling Its Role in Cancer Treatment and the Rise of Biosimilars(Post)Quick Facts About EnfortumabWhat is Enfortumab Vedotin?Enfortumab vedotin is an innovative cancer therapy, primarily used in treating urothelial carcinoma (bladder cancer) that has not r
The Bioelectronic Revolution: How Vagus Nerve Stimulation is Redefining Autoimmune Therapy(Post)Imagine a future where chronic autoimmune diseases, once managed by powerful pharmaceuticals with challenging side effects, are instead calmed by a gentle electrical pulse. This isn't science fiction
Flow Cytometry Gating: A Comprehensive Guide(Post)Techniques · Flow CytometryFlow Cytometry Gating: A Comprehensive GuideGating is how flow cytometry data is turned into meaningful results — a series of regions drawn on scatter and fluorescence plots
Privacy Policy(Page)Reagent Genie Website priva
Cyclins and Cyclin Dependent Kinase – Review(Post)Cell Cycle · KinasesCyclins and Cyclin-Dependent Kinases: Regulation, Substrates and Mitotic ControlCDKs are inactive on their own. They require a cyclin partner, and because cyclin levels rise and fa
T Cell Types, Activation, Polarization & Function(Post)T Cell Types, Activation, Polarization & Function A comprehensive guide to T cells! Introduction T-cells, vital components of the immune system, encompass vari
Biosimilar: Expanding Access to Monoclonal Antibody-Based Therapies(Post)1. What is a Biosimilar? A biosimilar is a biologic medical product that is highly similar to an already-approved reference biologic. While minor differences in clinically inactive compon
Anti-PD-L1: Targeting Tumor Evasion with Immune Checkpoint Blockade(Post)IntroductionCancer cells have developed sophisticated mechanisms to evade the immune system, particularly through the inhibition of T-cell responses. One such mechanism involves the progr
TIGIT: A New Frontier in Cancer and Autoimmune Disease Immunotherapy(Post)TIGIT (T cell immunoreceptor with Ig and ITIM domains) has emerged as a promising target in cancer immunotherapy and the treatment of autoimmune diseases. As a checkpoint receptor, TIGIT
Secukinumab: A Comprehensive Guide to Its Mechanism, Applications, and Biosimilar Advancements(Post)Quick Facts About SecukinumabWhat is SecukinumabSecukinumab is a monoclonal antibody that targets interleukin-17A (IL-17A), a key cytokine involved in inflammatory and autoimmune respons